When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
Omeros is unique. It's different from other clinical-stage biotechs in that it has an FDA-approved drug (Omidria) in the market generating revenue to fund ongoing clinical developments.
Now, the Omidria reimbursement overhang is gone after CMS confirmed a separate payment mechanism, which partially derisked the business.
After years of struggle and almost no return to shareholders, Omeros finally sees the light at the end of the tunnel.
The submitted narsoplimab BLA and upcoming approval could provide much higher upside potential.